Jiangsu, China

Shuli Ma


 

Average Co-Inventor Count = 9.9

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Shuli Ma: Innovator in Antibody Therapeutics

Introduction

Shuli Ma is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-based therapies. With a total of 5 patents to his name, his work focuses on innovative treatments for various diseases, including colorectal cancer.

Latest Patents

One of Shuli Ma's latest patents is related to Anti-CD137 antibodies and methods for treating colorectal cancer using them. This invention describes an antibody capable of specifically binding to CD137 or an antigen-binding fragment thereof. The antibody may include mutations in the light chain variable region and the heavy chain variable region, enhancing its therapeutic potential. Another notable patent is the IL-10 EGFR antibody fusion protein, which encompasses proteinaceous complexes, pharmaceutical compositions, and methods for producing these complexes. These innovations highlight his commitment to advancing medical treatments through targeted therapies.

Career Highlights

Shuli Ma has worked with several notable companies in the biotechnology sector, including Dingfu Biotarget Co., Ltd. and Shihuida Pharmaceutical Group (Jilin) Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in antibody therapeutics.

Collaborations

Throughout his career, Shuli Ma has collaborated with various professionals in the field. Notable coworkers include Jianjian Peng and Hui Ma, who have contributed to his research endeavors and innovations.

Conclusion

Shuli Ma's work in the field of antibody therapeutics exemplifies the impact of innovative thinking in biotechnology. His patents and collaborations reflect a dedication to improving treatment options for patients, particularly in the area of cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…